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Abstract 
Background: Diabetes consumes between 5% and 10% of most countries’ health budgets 
with the majority of the costs being for hospitalisation, making analysis of hospital costs an 
integral part in the estimation of the costs of managing diabetes and its complications. 
Analysing direct costs makes a greater impact as these are costs that the healthcare 
professional best understands and deals with on a daily basis. The number of diabetes 
patients is on the increase worldwide with type 2 being the most prevalent and South Africa 
is no exception. The number of type 2 diabetic patients is expected to grow by 9% per annum 
and by 2012 will comprise about 93% of the entire diabetic population in South Africa. 
Diabetes mellitus was the sixth leading cause of death in 2008 in South Africa.  
 
Aim: The main aim of the study was to compare the costs and length of hospitalisation 
between diabetic and non-diabetic patients for a cross-section of patients discharged with 
cerebrovascular diseases, ophthalmic conditions, cardiovascular diseases, renal conditions, 
neurological diseases (of the peripheral nervous system) and peripheral vascular diseases.  
 
Methods: A cross-sectional retrospective audit of medical records of all patients 
discharged from Chris Hani Baragwanath Academic Hospital with the above mentioned 
six specific conditions between 1
st 
and 31
St
 December 2009 was conducted. These patients 
were identified using Medicom®, the hospital’s software system, and then grouped by ICD-
10 codes listed on the database. The medical records were then manually analysed to 
determine the diabetes status of the patients, obtain information on lab tests and medical 
procedures performed and drugs prescribed during the admission period for which the patient 
was discharged during the period of the 1
st
 to 31
st
 December 2009. The frequency of 
hospitalisation of these patients during 2009 was also investigated. 
 
Results:   
Diabetic patients comprised 38.08% (N= 407) of the study sample. Average total 
hospitalisation costs per patient were significantly higher for diabetic cohorts; R27 216-06 ± 
R19 476-65 compared to R18 185-05 ± R16 725-90 for the non-diabetic patients, p<0.00001. 
The average length of stay for diabetic patients was longer; 13.04 ± 9.29 days vs. 8.86 ± 8.33 
days (p<0.00001) for non-diabetic patients. Average admission rate per patient per year in 
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2009 was higher in diabetic patients 1.8 ± 0.8 times vs. 1.5 ± 0.6 times in non-diabetic 
patients, (p<0.00004).   
 
Conclusion:  
This study showed that patients with diabetes had higher costs and longer in-patient stays 
than non-diabetic patients for the admission episode for which they were discharged between 
1
st
 and 31
st
 December 2009. Diabetic patients’ average total hospitalisation costs were 44% 
more than that of non-diabetic patients. Diabetes patients had a significantly higher average 
frequency of hospitalisation per patient for the year 2009. Cardiovascular disease was the 
most prevalent in both groups. Results from this study should be used to advocate for 
improved diabetes prevention awareness, improved patient understanding of the reasons for 
strict diabetes control measures and keen attendance in out-patient clinics to avoid 
unnecessary hospitalisation which leads to increased costs. 
- 
 v 
Acknowledgements 
I would like to express my sincere gratitude to the following people, without whom this 
project would never have seen the light of day: 
 Prof P. Danckwerts- My supervisor 
 Ms Maria Matabane and Sphiwe  Ndlovu - IT Department CHBAH  
 Ms Vuyo Gibson - Records and Filing CHBAH 
 Dr Bruno Pauly -  Diabetes Centre CHBAH 
 Dr Dumburashe - NHLS, CHBAH 
 Prof A.G. Gous –MSc Med Lecturer 
 
 
- 
 vi 
Dedication 
I dedicate this project to the memory of my mother, the unsung heroine whose sacrifices 
nurtured and instilled the belief in my capabilities. I am grateful to both my parents for this 
wonderful set of genes, and to my family; Nqoe, Mimi and Ntonga for their great sense of 
humour that makes my world a brighter place. 
- 
 vii 
DECLARATION ..................................................................................................................................................... II 
ABSTRACT ...............................................................................................................................................................III 
LIST OF ABBREVIATIONS AND ACRONYMS ............................................................................................................. IX 
CHAPTER 1 : INTRODUCTION ............................................................................................................................................. 10 
1.1 BACKGROUND .................................................................................................................................................. 10 
1.2 RATIONALE FOR THE STUDY ............................................................................................................................. 12 
1.3 AIM OF THE STUDY ........................................................................................................................................... 15 
1.4 SPECIFIC OBJECTIVES ........................................................................................................................................ 15 
1.5 STUDY OVERVIEW ............................................................................................................................................ 16 
CHAPTER 2 : LITERATURE REVIEW ................................................................................................................................. 17 
CHAPTER 3 : METHODOLOGY ............................................................................................................................................ 25 
3.1 STUDY POPULATION ......................................................................................................................................... 25 
3.2 SAMPLE INCLUSION/EXCLUSION CRITERIA ....................................................................................................... 25 
3.3 SAMPLING PROCEDURE ..................................................................................................................................... 26 
3.4 IDENTIFICATION OF DIABETES PATIENTS ........................................................................................................... 26 
3.5 Costing method ................................................................................................................................................ 27 
3.5.1 Lodging costs (Board and room) .................................................................................................................. 27 
3.5.2 Laboratory tests and medical procedures costs ............................................................................................. 29 
3.5.3 Pharmaceuticals costs ................................................................................................................................... 29 
3.6 HOSPITALISATION RATE ................................................................................................................................... 29 
3.7 DATA ANALYSIS ............................................................................................................................................... 30 
3.8 ETHICAL CLEARANCE ....................................................................................................................................... 30 
CHAPTER 4 RESULTS ............................................................................................................................................................. 31 
4.1 SAMPLE CHARACTERISTICS .............................................................................................................................. 31 
4.2 COST RESULTS .................................................................................................................................................. 33 
4.3 LENGTH OF HOSPITALISATION (IN-PATIENT DAYS) ........................................................................................... 36 
4.4 TOTAL COSTS OF HOSPITALISATION .................................................................................................................. 36 
4.5 COST OF PHARMACEUTICALS ............................................................................................................................ 38 
4.6 COST OF LABORATORY TESTS AND PROCEDURES .............................................................................................. 39 
4.7 AVERAGE RATE OF HOSPITALISATION PER PATIENT PER YEAR (IN 2009) .......................................................... 40 
CHAPTER 5 DISCUSSION AND LIMITATIONS ................................................................................................................. 41 
5.1 DISCUSSION ...................................................................................................................................................... 41 
5.2 LIMITATIONS OF THE STUDY ............................................................................................................................. 45 
CHAPTER 6 CONCLUSIONS AND RECOMMENDATIONS ............................................................................................. 47 
6.1 CONCLUSIONS .................................................................................................................................................. 47 
6.2 RECOMMENDATIONS ........................................................................................................................................ 48 
6.3 IMPLICATIONS FOR THE PHARMACIST ............................................................................................................... 49 
CHAPTER 7 ................................................................................................................................................................................ 50 
REFERENCES .......................................................................................................................................................... 50 
APPENDICES ............................................................................................................................................................................. 53 
1. DATA COLLECTION FORM .......................................................................................................................... 53 
2. CHRIS HANI BARAGWANATH ACADEMIC HOSPITAL INPATIENT ADMISIONS AND 
DISCHARGES BY MONTH 2009 ........................................................................................................................ 55 
3. MEDICAL SUPPLIES PRESCRIBED FOR THE STUDY PATIENTS ........................................................... 56 
4 ETHICS CLEARANCE ...................................................................................................................................... 61 
5. PROTOCOL APPROVAL ................................................................................................................................ 62 
 
 
 
- 
 viii 
TABLE OF FIGURES 
FIGURE 1.1 GLOBAL TRENDS AND THEIR IMPACT ON PHARMACO-ECONOMICS OF DIABETES. ADAPTED FROM 
BOTTOMLEY & RAYMOND 2007 ................................................................................................................. 11 
TABLE 1.1: THE TEN LEADING UNDERLYING NATURAL CAUSES OF DEATH FOR MALES AND FEMALES IN SOUTH 
AFRICA, 2008 BASED ON ICD-10 (1992). (ADAPTED FROM STATISTICS SOUTH AFRICA,   2010) ................ 13 
TABLE 3.2 NUMBER OF PDE AND COST PER PDE PER MONTH (OCTOBER-DECEMBER 2009) PROVIDED BY CHBAH 
INFORMATION TECHNOLOGY DEPARTMENT ................................................................................................ 28 
TABLE 3.3 CALCULATION OF THE COST OF BOARD AND ROOM (LODGING) PER MONTH (OCTOBER TO DECEMBER 28 
FIGURE 4.1 STUDY SAMPLE IDENTIFICATION PROCEDURE ..................................................................................... 31 
TABLE 4.1 ALL PATIENTS (DIABETIC AND NON-DIABETIC) DISCHARGED WITH THE REQUIRED CONDITIONS IN 
DECEMBER 2009 AS PER MEDICOM® .......................................................................................................... 32 
TABLE 4.2: STUDY PATIENTS CATEGORIZED BY CONDITION AND STRATIFIED BY DIABETES STATUS ..................... 33 
TABLE 4.3: SUMMARY OF RESULTS FOR TOTAL IN-PATIENT DAYS AND TOTAL COSTS FOR LODGING, LABS & 
PROCEDURES AND PHARMACEUTICALS ....................................................................................................... 34 
TABLE 4.4 SUMMARY OF MEAN VALUES (± S.D) FOR IN-PATIENT DAYS AND COST VALUES .................................. 35 
FIG 4.2 AVERAGE HOSPITAL STAY PER PATIENT .................................................................................................... 36 
FIG 4.3 AVERAGE TOTAL COST OF HOSPITALISATION PER PATIENT ....................................................................... 37 
FIG. 4.4 AVERAGE COST OF PHARMACEUTICALS PER PATIENT .............................................................................. 38 
FIG. 4.5 AVERAGE COST OF LABORATORY TESTS AND PROCEDURES PER PATIENT ................................................ 39 
FIG. 4.6 AVERAGE RATE OF HOSPITALISATION PER PATIENT PER YEAR ................................................................. 40 
- 
 ix 
List of Abbreviations and Acronyms 
 
AIDS    Acquired Immuno Deficiency Syndrome 
CHBAH    Chris Hani Baragwanath Academic Hospital 
CVD    Cerebrovascular Disease 
CVS     Cardiovascular System 
DKA    Diabetic Keto-Acidosis 
DRG    Diagnostic Related Group 
HIV     Human Immuno Deficiency Virus 
ICD-10  The International Statistical Classification of Diseases and 
Related Health Problems, 10th Revision  
ICU     Intensive Care Unit 
IDF     International Diabetes Federation 
IT     Information Technology 
Medicom®   Hospital Computer Software 
MIMS    Monthly Index of Medical Specialties 
NDoH     National Department of Health 
Neuro    Neurologic 
NHLS    National Health Laboratory Services 
Ophth    Ophthalmic 
PDE      Patient Day Equivalent 
PVD    Peripheral Vascular Disease 
RCT     Randomised Control Trials    
RVU     Relative Value Unit 
TB    Tuberculosis 
USA     United States of America 
WHO    World Health Organisation 
- 
 10 
Chapter 1 : Introduction 
1.1 Background 
 
Chris Hani Baragwanath Hospital is located in Soweto, Johannesburg and is the largest hospital 
in South Africa with 2982 useable beds. The hospital had an annual expenditure of nearly 2 
billion Rands in 2009 with 132 313 in-patient admissions in that year. (CHBAH 2009.) Patients 
are admitted to the hospital with a wide range of medical conditions of varying severity coming 
from the surrounding Johannesburg areas, other parts of South Africa and from neighbouring 
countries such as Zimbabwe, Lesotho, Mozambique, Swaziland and Zambia. It is a public 
academic hospital specialising in diverse clinical disciplines such as internal medicine, 
oncology, renal, cardiology, endocrine, psychiatric and various paediatric specialties. 
 
Diabetes is a modern day pandemic (Bottomley & Raymond 2007) whose prevalence is on the 
rise worldwide and South Africa is no exception. Frost and Sullivan (2007) estimated that  type 
2 diabetic population in South Africa is expected to grow by 9% per annum, and by 2012 will 
comprise about 93% of the entire diabetic population in South Africa. Diabetes was the sixth 
leading cause of death in males and seventh in females during 2008, contributing 2.6% (n= 302 
744) of the deaths in males and 4.1% (n=288 544) in females ahead of other public health 
priorities like HIV/AIDS (Statistics South Africa 2010). South African diabetes statistics 
estimates from the International  Diabetes Federation (IDF 2010) indicate that there was a 4.5% 
prevalence of diabetes in the age group 20 to 79 years, 45 957 deaths attributable to diabetes 
and a mean health expenditure per person with diabetes of US$ 674 in 2010. 
 
A search on the hospital’s Medicom® database by the author revealed that of all hospital 
discharges at CHBAH, in December 2009, more cases of documented diabetic patients (ICD-10 
codes E10; E10.0; E10.1; E10.4; E10.9; E11, E11.5; E13.1; E14; E14.1; E16.1; E16.2; and 
R73.9) were discharged than either HIV or TB (4.1% vs. HIV 3.24% and TB 1.93%  
(n= 10 171).  This therefore implies that diabetes may be a significant contributor to the 
overall healthcare expenditure at CHBAH in particular and in South Africa generally. 
Hence, a study of the cost of diabetes care is warranted. 
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Diabetes’ pharmaco-economics is influenced by many factors as noted in Fig. 1.1. These 
include the increasing diabetic patient population, increased healthcare resources used as new 
and more costly treatment modalities become available, clinicians’ desire to treat to target and 
pressures to control costs among other factors. 
 
 
 
 
RCT- Randomised Control Trials    
Figure 1.1 Global trends and their impact on pharmaco-economics of diabetes. Adapted from 
Bottomley & Raymond 2007  
Given the high number of cost drivers associated with diabetes as noted above, the medical 
research community is likely to have a difficult time reaching a uniform method of defining its 
cost (Campbell & Campbell 1997). However despite the fact that estimation of the total direct 
costs of diabetes may be difficult to achieve due to paucity of cost data and underreporting of 
diabetes in most hospital records, cost of hospitalisation can still be estimated. 
  
About half of all the money spent on diabetes care goes towards the costs of managing diabetic 
complications with cardiovascular complications being the most prevalent. The trend of 
escalating diabetes prevalence with its impact on cardiovascular disease will, in all likelihood 
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lead to an immense financial burden in many countries unless action is taken to prevent both 
diabetes and its complications. (IDF 2003.) The increased use of resources by diabetic patients 
is related to a range of factors which include higher out-patient costs, higher pharmaceutical 
costs, higher rates of hospitalisation and longer hospital stays (Gilmer et al 2005).  
1.2 Rationale for the study 
 
Diabetes is on the increase in South Africa and was among the top seven causes of death in 
2008, (see Table 1.1), making a case for the investigation of its economic burden. To date, very 
few studies have been done on the comparison of hospitalisation costs incurred in the care of 
diabetic patients with the costs for non-diabetes patients admitted with diseases commonly seen 
in chronic diabetes in South Africa. The conditions chosen were based on the organ systems 
most affected in chronic diabetes. The International Diabetes Federation (2003) states that 
although evidence of tissue damage can be found in many organ systems, it is the kidneys, eyes, 
peripheral nerves and vascular tree, which manifest the most significant, and sometimes fatal, 
diabetic complications. Therefore, it was decided that a study on the comparison of 
hospitalisation costs between diabetic and non-diabetic patients for six specific diseases i.e. 
cerebrovascular, ophthalmic, cardiovascular disease, renal conditions, neurological diseases (of 
the peripheral nervous system) and peripheral vascular diseases at Chris Hani Baragwanath 
Academic Hospital was needed in order to determine if it is consistent with the trends in other 
countries. 
 
Hospital costs contribute a significant portion to the total cost of caring for patients with 
diabetes and this can be estimated within a geographic area in a given country (Gagliardino et 
al, 2000). Chris Hani Baragwanath Academic Hospital (CHBAH) located in 
Johannesburg was chosen as the study site for the comparison of hospitalization costs 
between diabetic patients and their non-diabetic counterparts because the vast majority 
of diabetes cases in South Africa are managed at the study site given its size of 2 625 
useable beds. Studies published by Pepper et al (2007) at GF Jooste Hospital (with 
200 beds) and van Zyl and Rheeder (2009) at Kalafong Hospital  with 700 beds 
indicate that fewer patients are seen at the smaller institutions. For instance, in 
Pepper et al’s study, there were only 53 cases of hyperglycemic admissions in two 
months and only 164 cases of all types of diabetic admissions documented at 
Kalafong Hospital over a period of 8 months. In contrast, there were 73 cases of 
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hyperglycemia admitted at CHBAH and 207 cases of other acute diabetic 
complications (diabetes coma, DKA, complications of gestational diabetes and 
hypoglycemia) in the month of December 2009, as documented on Medicom®. 
Hence analysis of cost of care between the two groups at CHBAH is desirable and may 
prove useful. Moreover, analysis of these direct costs makes a greater impact as these are costs 
that the healthcare professional best understands and deals with on a daily basis, (Campbell 
&Campbell, 1997). Furthermore, the International Diabetes Federation (2003) 
recommended that decision makers should evaluate the economic impact of diabetes and 
determine how this impact compares with that of other health problems. 
Table 1.1: The ten leading underlying natural causes of death for males and females in South 
Africa, 2008 Based on ICD-10 (1992). (Adapted from Statistics South Africa,   2010) 
 
Condition Males Females 
 Rank Number Percentage Rank Number Percentage 
Tuberculosis 
(A15-A19) 
1 41 034 13.6 1 33 746 11.7 
 Influenza and 
Pneumonia 
(J10-J18) 
2 22 243 7.3 2 23 290 8.1 
Intestinal 
infectious 
diseases (A00- 
A09) 
3 18 187 6.0 3 21 095 7.3 
Other forms of 
heart disease 
(I30-I52) 
4 11 862 3.9 4 14 511 5.0 
Cerebrovascular 
disease (I60-
I69) 
5 10 170 3.4 5 14 187 4.9 
Chronic lower 
respiratory  
diseases (J40-
J47) 
6 8 392 2.8 N/A   
Diabetes (E10-
E14) 
7 7 738 2.6 6 11 814 4.1 
HIV (B20-B24) 8 7 210 2.4 9 7 873 2.7 
Ischaemic Heart 
Disease (I20-
I25) 
9 7 026 2.3 N/A   
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Condition Males Females 
 Rank Number Percentage Rank Number Percentage 
Certain 
disorders 
involv. Immune 
mechanisms 
(D80-D89) 
10 6 599 2.2 8 8 029 2.8 
Hypertensive 
diseases (I10-
I15) 
N/A   7 8 741 3.0 
Other viral 
diseases (B25-
B34) 
N/A   10 6 475 2.2 
Other natural 
causes 
 121 788 40.2  126 644 43.9 
Non-natural 
causes 
 40 495 13.4  12 336 4.3 
All causes  302 744 100  288 544 100 
 
 
 •What is the economic impact of diabetes? 
 
Diabetes consumes between 5% and 10% of most countries health budgets with the majority of 
the costs being for hospitalisation. However most policy makers in developing countries do not 
know how costly the burden of diabetes is, on their healthcare systems. Consequently, this has 
led to huge gaps in available information which makes it difficult to analyse costs in most 
developing countries. (Gagliardino et al 2000.) This view is supported by the IDF (2003) which 
contends that there is no data in many countries to quantify the burden of diabetes financially 
yet hospital in-patient costs for the treatment of diabetic complications are the largest single 
contributor to direct healthcare costs worldwide. By comparing costs between diabetic and non-
diabetic patients, the results obtained will in part help to answer this question at CHBAH. 
 •How does this impact compare with that of other current health problems? 
A database search on Medicom® by the author revealed a relatively high incidence of 
documented (according to ICD-10 codes) diabetes-related admissions in December 2009, 
relative to other prevalent diseases like HIV/AIDS and TB. Given this information and the 
costly budget in operation at CHBAH it is important to compare the costs incurred in the care 
of diabetes patients to the costs for non-diabetes patients with similar chronic conditions as a 
starting point.  
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By conducting this study it is hoped that some contribution to the available literature can be 
made which will assist in diabetes financial monitoring and strengthening the referral system so 
that only critical cases are seen at CHBAH. This study’s findings may also be used to promote 
diabetes education and prevention of hospitalisations due to diabetes complications which are 
preventable with quality out-patient care and adequate patient self-management of their 
condition, (Jiang et al 2003). 
 
1.3 Aim of the study  
 
This study compared the total costs of hospitalisation between diabetic and non-diabetic 
patients admitted in hospital for similar disease conditions. The study’s aim was to describe the 
difference in hospitalisation costs and length of hospitalisation between diabetic and non-
diabetic patients in a cross-section of patients discharged during the same period with 
cerebrovascular, ophthalmologic, cardiovascular disease, renal conditions, neurological disease 
(of the peripheral nervous system) and peripheral vascular diseases at Chris Hani Baragwanath 
Academic Hospital. The cost and length of stay data collected was limited to the specific 
admission episode for which the patient was discharged between December 1
st
 and 31
st
 2009. 
The number of times these patients were hospitalised during the course of 2009 was also 
documented. 
 
1.4 Specific objectives 
a) To extract from the Medicom® database, hospital discharges at Chris Hani Baragwanath 
Hospital (CHBAH) from 1
st
 to 31
st
 December 2009 for patients diagnosed with 
cerebrovascular, ophthalmic, cardiovascular disease, renal conditions, neurological 
disease (of the peripheral nervous system) and peripheral vascular diseases  
b) To categorise these discharges by diabetes status in each diagnostic group through a 
manual review of patients’ medical files. 
c) To compare the mean length of stay in each diagnostic group between diabetic patients 
and non-diabetic patients. 
d) To calculate the cost of board and room per day from the cost per Patient Day 
Equivalent (PDE) provided by the IT department for the patients discharged during the 
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above mentioned period. 
e) To calculate and compare the cost of pharmaceuticals and laboratory tests and 
procedures for diabetic and non-diabetic patients. 
f) To calculate and compare the total cost of hospitalisation for diabetic and non-diabetic 
patients per diagnostic group for the discharge episode that occurred during this period. 
g) To document the frequency of hospitalisation during 2009, for diabetic and non-diabetic 
patients. 
 
1.5 Study overview 
 
The first chapter deals with the introduction, discusses the rationale of the study leading to the 
aims and objectives of this paper. The second chapter is a summary of the literature that the 
researcher went through that relates to the comparison of cost of care of diabetes patients with 
that of non-diabetes patients and the methods utilised in carrying out these studies. The 
literature is quoted from local, regional and international studies. Chapter three deals with the 
methods used in conducting the study and in the analysis of the data collected. The results of 
the study are outlined in chapter four with the discussion of the results and limitations of the 
study following in chapter five. The conclusions drawn from the results of the study and 
consequently recommendations arising from the analysis of the results make up chapter six. The 
last chapter is a list of references used in the write up and the appendices attached. 
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Chapter 2 : Literature Review 
 
From a literature search, most studies performed in the developed world utilised the Diagnostic 
Related Group (DRG) concept to assign costs, (Colin et al (2007), Olveira-Fuster et al (2004), 
Gargliardino et al (2004) and Carral et al (2002)). DRGs are based on the case mix and are 
assigned by a computerized program based on the ICD-10 code, diagnoses, surgical procedures, 
age, sex and discharge status. The cost per DRG point is the same regardless of the number, 
scope or intensity of services utilised. However, there were two studies on diabetes performed 
in Denmark by Kornum et al (2008) and Maldonado et al (2003) in the USA respectively that 
helped formulate the methodology for the present study in addition to the study done by 
Thomas (2006) at CHBAH on costing of HIV services. 
 
The International Classification of Diseases (ICD) is the World Health Organisation (WHO) 
international standard diagnostic classification for all epidemiological data and is also used for 
clinical and health management purposes. It is used to classify diseases and other health 
problems recorded on medical records including death certificates. In addition to enabling the 
storage and retrieval of diagnostic information for clinical, epidemiological and quality 
purposes, these records also provide the basis for the compilation of national mortality and 
morbidity statistics by WHO Member States. (WHO 2004.) The ICD-10 classification is 
used to categorise patients by medical conditions on the Medicom ® database. 
 
 
Kornum et al (2008) in a study in Denmark examined whether diabetes was a risk factor for 
hospitalisation in patients with pneumonia. They first identified patients with pneumonia using 
the hospital registries and associated ICD-10 codes. From this group of pneumonic patients, 
they then identified patients who were diabetic using the prescription database. They identified 
patients with at least one recorded prescription for insulin or an oral hypoglycemic agent as 
being a diabetic patient.  
 
A similar method to Kornum et al’s (2008) of identifying patients was applied to the present 
study. A database search was performed on Medicom® to establish which patients had been 
diagnosed with the six diseases associated with chronic diabetes. After identifying these 
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patients, a manual inspection of their medical records was then carried out to identify who 
amongst them was diabetic. The only difference is that Kornum et al (2008) were able to map 
out the diabetic status using the electronic databases whereas in the present study a physical 
analysis of files had to be used because no such information is available on Medicom® and the 
pharmacy uses manual records. The downside of physical file inspection is that it is totally 
dependent on the ability of the records department to keep files in order and if a file is lost or 
pages fall out, then the integrity of the data collected is compromised. 
 
Maldonado et al (2003) analysed in-patient costs of treating diabetic keto-acidosis (DKA) in a 
hospital in Houston, USA. The information on in-patient resource utilization for treating each 
patient with DKA was obtained from the hospital’s Resource Utilisation Department and 
itemized costs were recorded. Cost information for their study was recorded in specific 
categories viz: laboratory, hospital room (per day), ICU days, radiological tests, medical 
supplies, electrocardiograms, respiratory therapy, emergency room, operating room, physical 
therapy, occupational therapy, cardiologic tests, renal dialysis and anesthesia. In their study 
costs for laboratory tests and radiological procedures were calculated using a weighted 
procedure method in which each test or procedure is allocated a certain weight or a number of 
relative value units (RVU). Each relative value unit or weight is allocated a certain monetary 
value. Therefore the cost, for instance of two chest X-rays, using an RVU of 2 for a chest X-ray 
and an RVU being equivalent to US $4 will be US $8. Pharmaceuticals, intravenous therapy 
and supplies were calculated using the surcharge method in which the hospital applied a 25% 
surcharge on the cost value. Emergency room and ICU were calculated using a standardized 
hourly rate method of $45/hour for Emergency Room and $60/hour, at the time, for ICU. The 
costs for room and board which includes such services as maintenance, laundry, housekeeping, 
etc were calculated using the “per diem” method in which each day in hospital was assigned a 
cost of $385. This method is similar to that used by Thomas (2006) in the costing of HIV 
services at CHBAH. 
 
Pepper et al (2007) studied the financial implications of hyperglycemic emergencies at GF 
Jooste Hospital in Cape Town, South Africa using the ingredient approach which takes into 
account all individual cost components used. Their total costs included patient specific costs, 
(medication, lab tests, procedures and clinical staff costs) and non patient-specific costs - 
capital costs (which included building and equipment), and overhead costs. They collected data 
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prospectively for each component of the patients’ admission from arrival at the emergency unit 
to admission in the ward and discharge. The duration of stay in each department, doctor’s 
consultation, laboratory investigations, nursing costs per emergency visit and in-patient days 
were itemized. Capital cost and overhead costs were obtained from a previous study carried out 
in their study site. Although Pepper et al (2007) performed their study in a public hospital with 
similar opportunities and constraints to CHBAH; theirs is more suitable to a prospective study 
which could not be applied to the present retrospective analysis. With Pepper et al’s (2007) 
method, the researcher has to be present to actively observe the patient from the time the patient 
presents, throughout their stay until the point of discharge or death. Consequently Thomas’ 
method, which is described briefly below, was the preferred one for this study as it was a 
retrospective database search. 
 
In a study of costing of HIV services at CHBAH Thomas (2006) used the cost per patient day 
equivalent (cost per PDE) method. A patient day equivalent (PDE) is the equivalent of one 
patient staying in hospital for one full day. The cost of one PDE is the cost of caring for one 
patient for one full day in hospital. The patient day equivalent method utilises patient volumes 
(in-patient days, day patients, casualty patients and out-patients) each contributing a certain 
weight to the total hospital expenditure per given month as shown in equation 1 and 2 below. A 
day patient is a patient that undergoes a medical procedure in the hospital that does not require 
overnight stay. The hospital expenditure includes all costs - capital costs, overhead costs, 
maintenance, electricity, room and board, consumables, etc. The PDE is calculated every month 
using the data for in-patient days, day patients, casualty and out-patient head counts as shown 
below.  
Calculation of Patient Day Equivalent (PDE) (all values are per month) 
 
 Average Cost per PDE      =  Total monthly expenditure       (2)    
      Calculated PDE for the month 
 
PDE = Number. of  
Day patients  
 
+ 
Number. of 
 In-patient 
days  
 
+ 
(Out-patient headcount + casualty head count) (1) 
 3 
 
2 
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For research purposes this method was modified so as to get the cost of board and room per 
patient per day. This is done by deducting from the total monthly expenditure, the patient-
specific costs like pharmaceuticals, laboratory tests and procedures. The remainder represents 
the cost of room and board per patient day, (see equation 3). These specific costs for 
pharmaceuticals and lab tests are assigned to the patient based on consumption. This method 
was used in the present study because as far as possible all overhead costs of the hospital are 
catered for in the PDE costing as it utilises the monthly actual overall expenditure for the 
hospital in its calculation.  
 
Cost of Board &room /day= {Total Monthly Expenditure - (Laboratory +Pharmaceuticals’ 
Expenditure)} ÷ PDE for the month. (3) 
Total hospitalisation cost per patient = (average lodging cost per day x number of days in 
hospital for the specific patient) + cost of pharmaceuticals used per specific patient for the 
hospital stay + cost of laboratory tests and procedures per specific patient for the 
stay)…………….. (4) 
 
The total costs of hospitalisation per patient then becomes the sum of board and room cost, 
pharmaceuticals, labs and procedures per patient,  for the hospital stay for which the patient 
was discharged between December 1
st
-31
st
 2009, (see equation 4). This method is similar to 
Maldonado et al’s (2003) technique of itemised costs for certain services and per diem costs for 
room and board. This was the preferred approach for the present study as the cost information 
is readily available from the IT department. The disadvantage of the cost per PDE method is 
that it is an average value which gives an upper limit to board and room costs incurred by a 
patient without catering for the obvious differences in resource utilisation between an ICU 
patient and a day patient. This drawback is set off slightly to an extent by the disaggregation of 
patient specific costs like drugs, Labs, and X-rays.  
 
According to the Uniform Patient Fee Schedule used for billing fee-paying patients in the 
public sector, a facility fee is charged for all fee-paying patients depending on the level of care 
utilised i.e. general ward vs. ICU. The facility fees are gazetted annually by the government 
using national average annual figures for expenditure and patient numbers for all institutions. 
This facility fee reflects the overhead costs such as electricity, provision of general equipment 
as well as the cost of consumables and staff salaries which are necessary in the provision of the 
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health care service to the patient. This system was devised to cut down itemised billing 
although itemising still remains for pharmaceuticals and assistive devices both whose costs 
fluctuate from time to time (NDoH 2000.) However the facility fee was not used in this study 
for overhead costs, instead the PDE method was used because the calculation of the cost per 
PDE uses actual expenditure for the month which is a more accurate reflection of the 
operational costs of running the hospital from month to month as opposed to using data 
obtained from national estimates for all hospitals whether or not actual expenditure differs. 
 
No study currently exists, to the best of my knowledge that deals with a comparison of 
hospitalisation costs between diabetes and non-diabetic patients in the South African public 
hospital context. However, Pepper et al (2007) and van Zyl & Rheeder (2009) carried out their 
studies on diabetes in GF Jooste Hospital (200 bed hospital) and Kalafong Hospital (700 bed 
hospital), respectively.  
 
Pepper et al (2007) analysed the duration of stay, reasons for admission and the cost incurred 
by the hospital in treating diabetic patients admitted for hyperglycaemic emergencies. In this 
study there were 53 hyperglycemic cases admitted during the two month period of 
investigation. They found that sepsis, non-compliance with therapy and newly diagnosed cases 
of diabetes were the predominant reasons for admission. The mean duration of stay was 4 days 
and mean cost per patient was R5 309 (in 2007).  
 
Van Zyl & Rheeder (2009) evaluated practices in the management of glycaemic control of 
diabetic in-patients at Kalafong Hospital, a secondary level hospital in South Africa. They 
conducted an audit of clinical hospital records of all diabetic adult patients hospitalised, 
regardless of the reason for admission or severity of disease over an eight month period. The 
median length of stay was 7.5 days with a range of 1-87 days. During the study period 164 
patients were admitted with diabetes. 
 
Given that  CHBAH is much bigger (2 625 beds)  than the two hospitals described above, the 
number of cases of acute diabetic complications admitted is likely to be much higher as 
exemplified by the data for December 2009, extracted from the Medicom® database. In just a 
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month, there were 73 cases of hyperglycemic admissions and 203 cases of other acute diabetic 
complications such as diabetic coma, DKA, hypoglycemia and gestational diabetic 
complications. This therefore implies that costs for care of these acute complications of diabetes 
are more likely to have a great impact on the hospital budget at CHBAH. 
 
Feleke and Enquselassie (2007) studied the cost of hospitalisation of diabetic patients admitted 
at a specialized hospital in Addis Ababa Ethiopia using a case control study. The study was 
conducted on 146 diabetic patients and 142 non-diabetic controls admitted to medical wards of 
a specialised hospital. They found that the average total cost of hospitalisation was significantly 
higher in diabetic patients than in the controls with p<0.03. Fifty-seven percent of these costs 
were used on treatment of acute and chronic complications of diabetes. The average treatment 
and laboratory costs were significantly higher among the diabetic patients, p=0.013 and 
p<0.001 respectively.  
 
In a Tunisian study by Soltani et al, (1993) based on admissions data, 5.9% of the study 
population was diabetic of which 39.4% of the cases were cared for at a university hospital. 
The mean hospital stay for diabetic patients was 10.3 days versus 8 days for all the other 
patients. The cost of hospital care was dependent on the level of care involved with lower 
costs for district hospitals and higher for the university hospital, US $173 vs. US $372 
respectively. 
 
A number of studies on comparison of hospitalisation costs between diabetic and non-diabetic 
patients have been documented in the developed world setting. Carral et al (2002) and Oliveira-
Fuster et al (2004) carried out such studies in Spain while Colin et al (2007) compared length 
of hospital stay between diabetic and non-diabetic patients in a French hospital. Gargliardino et 
al (2004) also did a similar study in La Plata, Argentina and these studies are summarized 
briefly below. 
 
Carral et al (2002) assessed the rate of hospital admissions, length of stay, readmissions, 
mortality and costs for both diabetic and non-diabetic patients in a Spanish hospital. They found 
out that those patients with diabetes accounted for 10.9% of total hospital discharges (2 453 
discharges), 15.3% of total stays (30 771 days) and 16.1% of total costs. They estimated a 
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hospitalisation rate of 135 per 1000 patients with diabetes compared with 95 per 1000 non-
diabetic patients. Diabetic patients were hospitalized, on average, for 4 days longer than non-
diabetic patients (12.5±14.5 (±SD) vs. 8.5±10.6 days; p<0.001) and had higher risks of 
readmission (RR: 1.47 (95% CI: 1.33–1.62)) and of mortality during the in-patient period (2.29 
(1.91–2.74)) than non-diabetic patients. The overall hospitalisation cost was significantly higher 
(55% higher) in diabetic than in non-diabetic patients.  They concluded that the hospital care 
resource utilisation and economic burden due to diabetes mellitus in the study hospital was 
substantial and disproportionate to the number of affected people. 
 
In another Spanish study, Olveira-Fuster et al (2004) estimated the excess hospitalisation, 
hospital days and in-patient costs attributed to diabetes in 37 Spanish hospitals during 1999 
through an analysis of all discharges. Excess costs were calculated as the difference between 
costs for diabetic patients and non-diabetic patients. The relative risk of hospitalization was 
estimated by dividing the rate of hospitalization of individuals with diabetes by the rate of 
hospitalization of individuals without diabetes. People with diabetes accounted for 9.7% of all 
hospital discharges, 13.8% of total stays and 14.1% of the total cost. Of the total cost for 
individuals with diabetes, 58.3% were excess costs, of which 47% were attributable to 
cardiovascular complications and 43% to admissions for co-morbid diseases. The rate of 
admissions during the study year was 145 per 1 000 inhabitants for individuals with diabetes 
compared with 70 admissions per 1 000 inhabitants for individuals without diabetes. 
 
Colin et al (2007) examined whether or not diabetic patients required more human and material 
resources than average in the medical management of the acute phase of diabetic complications. 
They restricted the analysis to in-patient care in a French setting for five cardiovascular events- 
stroke, myocardial infarction, unstable angina, cardiac revascularisation and cardiac arrest. 
They found that the average length of stay for patients with diabetes were significantly longer 
than that of non diabetic patients for cardiovascular events. The mean number of medical 
procedures by stay was also higher in the diabetic group. Hospital costs for diabetic patients 
with non -fatal stroke and non -fatal myocardial infarction were 23.9% and 10.4%, more than 
the average costs, respectively. For unstable angina and coronary revascularization, hospital 
costs were 6.1% and 9.1% higher than average costs respectively. The mean length of stay 
ranged from 6.6 to 16.3 days for diabetic patients as compared to a range of 4.7 to 12.8 days for 
non-diabetic patients for the different conditions. 
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Jiang et al (2003) in a study of multiple hospitalisations among diabetic patients in five 
American states, found out that among diabetic patients who had been hospitalised, 30% had 
two or more stays accounting for > 50% of total hospitalisations and hospital costs. Results 
revealed that among diabetic patients with multiple stays, about 90% of adults had 
cardiovascular diseases, 25% had renal diseases and 40% had lower extremity diseases. They 
also found out that some of the multiple hospitalisations that resulted from these complications 
as well as some of the complications themselves were preventable with quality outpatient care 
and improved self-management of the condition. 
 
Gagliardino et al (2004) examined the prevalence, characteristics and costs of hospitalisation 
and re-hospitalisation of diabetic and non-diabetic patients in La Plata, Argentina. They studied 
all in-hospital registries of diabetic patients enrolled in a health maintenance organisation. For 
each of the 127 diabetic patients, characteristics of two other hospitalised non-diabetic patients 
matched by age and gender were simultaneously recorded. Of the recovered 2200 
hospitalisations, 5.8% were for diabetic patients, accounting for 10.5% of the hospitalisation 
costs. Cardiovascular diseases were the major causes of hospitalisation in both groups. Per 
capita hospitalisation costs for diabetic patients were significantly higher US $1 628-50 ± US 
$1 754 vs. US $833 ± US $842 p= 0.0002. Re-hospitalisation rate was five and a half times 
higher in diabetic patients (p=0.0001) and significantly associated with a history of severe 
episodes of acute complications (odds ratio 3.61 {95% CI 1.11-11.70} p = 0.03) and chronic 
complications (odds ratio 4.26; {95% CI 1.6- 11.29}; p =0.004). 
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Chapter 3 : Methodology 
3.1 Study Population 
The target group consisted of all patients discharged in December 2009 with cerebrovascular, 
ophthalmic, cardiovascular disease, renal conditions, neurological disease (of the peripheral 
nervous system) and peripheral vascular diseases as identified by the ICD-10 codes used on 
Medicom®. In this group a detailed audit of clinical records was done from September 2010 to 
November 2010, through a manual review of patients’ medical files to identify the diabetic 
patients, drugs prescribed and laboratory tests and medical procedures carried out on the 
patient. 
3.2 Sample Inclusion/Exclusion criteria 
 
All medical records for patients discharged from the medical wards over the period of 1
st 
- 31
st
 
December 2009 with cerebrovascular, ophthalmic, cardiovascular disease, renal conditions, 
neurological disease (of the peripheral nervous system) and peripheral vascular diseases were 
analysed. The month of December was chosen so as to meet the objective of calculating the 
annual hospitalisation frequency retrospectively for the study patients for the entire year from 
January to December 2009. Hence the hospitalisation frequency for those patients discharged in 
December took into account all the prior admissions that might have occurred during the year 
culminating in the admission episode/s that occurred in December. Patient records of those who 
died whilst in hospital were excluded. Neonatal and maternal discharges were excluded from 
the analysis. Maternal discharges were identified from Medicom® as starting with the prefix O- 
in the ICD 10 listing and neonatal as starting with the prefix P-. Only the records that have all 
the following information were included in the analysis for both diabetic and non-diabetic 
patient files:- 
3.2.1 Patient demographic details- age, sex, hospital number (GT or GP Number) 
This information was necessary to match the information on Medicom® with the patient 
file in order to identify the study subjects. 
3.2.2 Doctor’s notes with discharge diagnosis written on the patient file and signed for 
with the name and qualifications of the attending doctor. The researcher had to confirm 
on the patient file if the Medicom® ICD-10 assigned to the patient’s discharge diagnosis 
matched with the description of the patient’s condition on the file in order to allocate the 
patients in the relevant diagnostic group. 
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3.2.3 Dates of admission and discharge 
To ensure that the data collected for pharmaceuticals and procedures was for the 
discharge episode required for the study 
3.2.4 Treatment details: procedures and laboratory tests ordered and medication 
prescribed, frequency and dosages 
This information was required for confirmation of diabetes status were none was 
specified. It was also used for costing of pharmaceuticals administered and medical 
procedures and laboratory tests done per patient. 
3.2.5 Nursing care notes as signed for by the nursing sister with the name of the 
attending nurse to help in identifying the patients’ disease conditions. 
3.3 Sampling procedure 
 
The discharge list obtained from Medicom® for the month of December 2009 was used as the 
primary source of data for the study subjects. Discharge data is stratified by ward and by ICD 
codes on the hospital Medicom® software system. From the Medicom® database, it was found 
that 10 171 patients were discharged over the month of December 2009. Of these, 685 were 
diagnosed with the selected conditions of interest according to the ICD codes and were then 
grouped by class of condition i.e. cardiovascular, neurological etc. Data collection was carried 
out retrospectively for the patients discharged in the month of December 2009. A similar 
method of identifying patients was used by Kornum et al (2008) in Denmark as mentioned 
above. 
3.4 Identification of diabetes patients 
 
A manual method of identifying diabetic patients from the discharge list had to be employed 
because the Medicom® database does not list other disease conditions as a secondary diagnosis 
where present other than the presenting condition e.g. diabetes status. Three steps were used to 
identify patients as diabetic using the patient’s hospital file. Firstly the researcher used the risk 
profile page (pink page) at the start of the in-patient file that lists the different chronic diseases 
among which diabetes is one. This list is used by the nursing care staff to identify patients 
admitted with the different conditions. Secondly the admitting doctor also has to specify on the 
admission file cover (blue cover) the different conditions the patient is suffering from including 
the provisional and final diagnoses. Lastly the pharmacy prescription chart was used wherever 
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there was doubt to check the medication history of the patient. If insulin or any of the oral 
hypoglycaemic agents were prescribed, it was then assumed that the patient was diabetic. Type 
of diabetes was not examined. 
 
3.5 Costing method 
 
The costing method used is similar to Maldonado et al (2003) and adapted by Thomas (2006) as 
mentioned above (see chapter 2). The total hospitalization cost is comprised of lodging costs, 
the cost of pharmaceuticals and medical procedures and laboratory costs (see equation 4). The 
mean total hospitalisation cost for diabetic and non-diabetic patients was compared within each 
disease group.  
 
Total hospitalization cost per patient = (average lodging cost per day x number of days in 
hospital for the specific patient)+ cost of pharmaceuticals used per specific patient for the 
hospital stay + cost of laboratory tests and procedures per specific patient for the 
stay)……………..(4) 
3.5.1 Lodging costs (Board and room) 
 
The cost per PDE as given by the hospital’s IT department was modified to calculate the 
lodging costs for each patient (see Table 3.3). For the purposes of this study, the expenditure for 
patient-specific items like pharmaceuticals and laboratory procedures was excluded in the 
calculation and these were calculated per patient as outlined in Chapter 2.  
PDE = Number of  
Day 
patients  
 
+ 
Number of 
 In-patient days  
 
+ 
(Out-patient headcount + casualty head count)  
(1) 
 3 
 
2 
 
Average Cost per PDE      = Total monthly expenditure       (2)     
                       Calculated PDE for the month 
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The average monthly PDE cost used was for the three months from October to December 2009 
(see Table 3.2). This was done to cater for the calculation of the hospitalisation cost for those 
patients that were admitted in November for instance, but discharged in December.
  
  
 
Average cost of Board &room /day= {Total Monthly Expenditure - (Laboratory 
+Pharmaceuticals’ Expenditure)} ÷ Average PDE for the month (3) 
 
Table 3.2 Number of PDE and cost per PDE per month (October-December 2009) 
provided by CHBAH Information Technology department 
 
Month Number 
of Day 
patients 
Number of  
Inpatient 
 Days  
Out- 
Patients’ 
Head count 
Casualty  
Head-  
Count 
Number of  
PDE 
(Equation 1) 
Total 
Expenditure* 
 (In Rands) 
Cost per PDE 
(In Rands) 
(Equation 2) 
Oct 3 285 65 765 38 427 10 012 83 554 220 694 137 2 641-34 
Nov 3 302 65 024 41 214 9 531 83 590 180 931 686 2 164-51 
Dec 3 283 59 608 42 533 9 271 78 518 145 509 323 1 853-20 
 
Table 3.3 Calculation of the cost of board and room (lodging) per month (October to December  
(2009) 
Month Total 
Expenditure* 
NHLS  
Expenditure** 
Pharmacy 
Expenditure*** 
Board & Room Cost 
(Equation 3) 
October R220 694 137 R12 632 211-07 R20 638 029-16  R2 243.15 
November R180 931 686 R12 853 278-69 R18 951 139-71  R1 784.03 
December R145 509 323 R10 443 390-09 R15 104 331-66  R1 527.82 
 
Figures obtained from CHBAH:   * Ms Maria Matabane IT Department 
      ** Ms Cecilia Venter Finance Department 
  *** Ms Tshilidzi Shabangu Drug Controller 
 
Average Board & room per day  =R (2243-15+1784-03+1527-82) ÷3 
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      = R1851-66 
Lodging costs for length of admission = R 1851-66 X Number of days in hospital………………… (5) 
 
Total hospitalisation cost per patient = (average lodging cost per day x number of days in 
hospital for the specific patient) + cost of pharmaceuticals used per specific patient for the 
hospital stay + cost of laboratory tests and procedures per specific patient for the stay) (4) 
3.5.2 Laboratory tests and medical procedures costs 
 
The costs of individual tests performed on each patient were calculated according to the fees 
charged by the National Health Laboratory Services (NHLS) as outlined in the NHLS State 
Price List of 2009. Cost of labour was not included in the calculation of laboratory costs 
because it is already incorporated in the invoiced amount to the hospital. Procedures e.g. 
radiology, theatre procedures, dialysis etc. for each patient were obtained from the files and the 
cost of procedures was calculated individually from the National Department of Health 
Uniform Fee Schedule 2009. The fees shown under facility level 3, specialist category were 
charged as per the billing procedure for fee-paying patients at CHBAH. The facility fee was 
excluded from the costs as this fee is the equivalent of PDE in this particular study. 
3.5.3 Pharmaceuticals costs 
 
Drugs given to patients were charged according to the pharmacy price list availed by the Drug 
Controller, Ms Tshilidzi Shabangu. This price list is used for audit purposes in costing the value 
of the stock at the end of the Financial Year. As with the laboratory costs, the labour costs of 
dispensing were not included because staff salaries form part of expenditure with which the IT 
department calculates the cost per PDE. Drugs prescribed for the patient and actually 
administered for the duration of the admission episode were obtained from individual patient 
files.  
3.6 Hospitalisation rate 
 
Hospitalisation rate for the study was defined as the number of times a specific patient was 
admitted into the hospital in the year 2009. The number of times a patient was hospitalised 
during 2009 was extracted from Medicom® using the unique patient identifier number with the 
prefix GP or GT. The annual average frequency of admission per patient for the year was 
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compared between diabetic and non-diabetic patients within diagnostic groups.  
3.7 Data analysis 
 
The total cost of hospitalisation and the length of admission for the discharge episode in 
December 2009 were entered in the data form and transferred into Microsoft Excel. The 
frequency of hospitalisation in 2009 was also entered. Statistical analysis was performed on 
Microsoft Office Excel 2003 using the student t-test and descriptive statistics with a p-value of 
<0.05 being significant. Tables and graphs were also used to present data by category.  
3.8 Ethical Clearance 
Ethics clearance was obtained from the Human Research (Medical) Ethics Committee of the 
University of Witwatersrand (appendix 4). 
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Chapter 4  Results  
 
The main aim of the study was to compare the hospitalisation costs and length of hospitalisation 
between diabetic and non-diabetic patients for discharges that occurred during December 2009.  
4.1 Sample characteristics 
 
Figure 4.1 and Table 4.1 show how many patients were eligible for analysis, using the study’s 
inclusion and exclusion criteria, from the Medicom® database search. There were 10 171 
patients discharged from CHBAH from December 1
st
 2009 to December 31
st
 2009. Of these, 
only 685 matched the inclusion criteria with 278 records not being available for analysis 
leaving 407 records to be studied as shown below on Figure 4.1. 
  
Figure 4.1 Study sample identification procedure 
 
10 171 patients 
discharged during 
December 2009 
685 patients discharged 
with required conditions 
(table 4.1) 
407 patient records 
analysed for the 
study 
9 486 Patient records that did not 
meet study criteria for chronic 
conditions to be studied 
278 records misplaced, lost 
or in the wards that 
researcher did not have 
access to. 
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Table 4.1 All Patients (diabetic and non-diabetic) discharged with the required conditions in 
December 2009 as per Medicom® 
 
Group ICD 10 Listing ICD 10 Condition Number 
Neurological G61.8 Polyneuropathies 14 
G62 Peripheral neuropathies 13 
 total 27 
Ophthalmic  H18.4 Corneal degeneration 10 
H26.9 Cataracts 58 
H33, H35.0 Retinal disorders 10 
H40.5 Glaucoma 12 
H46, Optic neuritis 13 
 total 103 
cardiovascular I42 Cardiomyopathy 28 
I10, I15, I15.8, I15.9 Hypertension 158 
I20.0, I21, I24, I25.5 Ischaemic heart disease 14 
I45.5, I46.9 Cardiac arrest 17 
I11, I11.0 Hypertensive heart disease 30 
I50, I50.0, I50.1, I50.9 Heart failure 101 
 total 348 
Cerebrovascular  
conditions 
G81, G81.9 Hemiplegia 27 
I67, I67.9 Cerebrovascular disease 51 
 total 78 
Vascular I73, I73.8, I73.9 Peripheral vascular diseases 33 
I81, I82.3, I82.9 Thrombosis 10 
 total 43 
Renal N04, N04.8, N04.9 Nephrotic syndrome 6 
 N11.0, N11.1, N13.0, N13.2 Nephritis 22 
 N17.0, N17.9 Acute renal failure 33 
 N18.0, N18.8, N19 Chronic renal failure 25 
  total 86 
Total   685 
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From this final sample size of 407 patient records, 155 (38.08%) were for diabetic and 252 
(61.92%) were non-diabetic patients (Table 4.2)  
Table 4.2: Study patients categorized by condition and stratified by diabetes status 
 
 
 
 
 
 
 
 
 
 
 
 
4.2 Cost results 
 
Table 4.3 below summarises the results in terms of totals for each disease condition. For 
these patients discharged in December 2009, diabetic patients spent a total of 2021 in-patient 
days while the non-diabetic patient spent 2233 inpatient days in hospital. Table 4.4 
summarises the mean values for diabetic and non-diabetic patients per disease group. 
 
Condition Non-diabetic Diabetic Total 
Cardiovascular 79 59  138 
Neurological 13  6 19 
Ophthalmic 49 29  78 
Renal 42  30  72 
Cerebrovascular 39  21  60 
Vascular disease 30 10 40 
Total 252 155 407 
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Table 4.3: Summary of Results for Total In-Patient Days and Total Costs for Lodging, Labs & Procedures and Pharmaceuticals 
 
Diabetic Patients Non-Diabetic Patients 
 Total costs in Rands for all patients  Total costs in Rands for all patients 
Condit
-ion 
N 
 
In-
pt 
days 
Lodging Labs &  
Procedur
e 
P’ceutical
s 
Total costs N In-
pt 
days 
Lodging Labs 
&Proced
ures 
Pharmace
uticals 
Total costs 
CVS 59 597 1 105 441-02 45,184.95 70,016.82 1,221,239.79 79 577 1 068 407-82 33,191.14 60,902.14 1,163,078.10 
Ophth 29 360 666 597-60 29,335.12 50,526.60 746,459.32 49 225 416 623-50 17,432.84 25,000.22 459,056.56 
Renal 30 410 759 180-60 54,604.67 64,594.64 878,789.91 42 310 574 014-60 28,690.38 48,746.60 651,451.58 
PVD 10 151 279 600-66 12,347.72 14,713.26 306,661.64 30 408 755 477-28 19,585.40 36,537.27 811,599.95 
Neuro 6 103 190 720-98 8,034.16 9,210.24 207,965.38 13 247 457 360-02 12,122.84 19,526.38 489,009.24 
CVD 21 400 740 664-00 42,966.39 73,742.63 857,373.02 39 466 862 873-56 53,689.78 91,874.41 1,008,437.75 
Totals 155 2021 3 742 204-86 192,473.02 282,804.14 4,218,489.02 252 2233 4 134 756-78 164,712.38 282,587.01 4,582,633.17 
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 Table 4.4 Summary of Mean values (± s.d) for In-patient days and cost values 
 
Diabetic Patients Non-Diabetic Patients 
Mean costs per patient ± s.d for all patients (2009 South African Rands) Mean costs per patient ± s.d for all patients (2009 South African 
Rands) 
Condit-
ion 
 In-
patient 
Days 
Lodging Labs & 
Procedures 
P’ceuticals  Total 
costs 
In-
patient 
Days 
Lodging Labs & 
Procedures 
P’ceuticals Total costs 
CVS Mean 10.11 18 736-29 765-85 
1 186-73 
20 698-98 7.30 13 524-15 420-14 770-91 
14 722-51 
S.D 6.97 12 902-58 908-66 1 087-63 14 281-93 5.86 10 851-17 342-88 720-67 
11 581-47 
Ophth Mean 12.41 22 986-12 1 011-56 1 742-30 25 739-98 4.59 8 502-52 355-77 510-21 
9 368-50 
S.D 11.41 21 126-77 1 171-25 1 996-07 23 894-02 4.05 7 492-16 294-68 489-26 
8 063-57 
Renal Mean 13.67 25 306-02 1 820-16 2 153-15 29 293-00 7.38 13 667-01 683-10 1 160-63 
15 510-75 
S.D 7.72 14 296-11 2 293-14 1 209-32 16 749-50 6.80 12 584-86 491-32 1 135-61 
13 948-15 
PVD Mean 15.1 27 960-07 1 234-77 1 471-33 30 666-16 13.60 25 182-58 652-85 1 217-91 27 053-33 
S.D 9.89 18 319-06 511-31 925-42 18 990-51 10.24 18 962-03 405-78 978-71 20 125-73 
Neuro Mean 17.17 31 786-83 2 295-47 2 631-50 41 881-51 19.00 35 181-54 932-53 1 502-03 37 616-10 
S.D 10.11 18 716-12 1 277-39 977-50 20 824-41 15.81 29 267-56 1 372-25 1 372-25 30 800-58 
CVD Mean 19.05 35 269-71 2 046-02 3 511-55 40 827-29 11.95 22 124-96 1 376-66 2 355-75 25 857-38 
S.D 10.69 19 791-78 1 282-86 1 812-55 22 373-56 8.06 14 916-16 589-68 2 163-76 16 943-15 
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4.3 Length of hospitalisation (in-patient days) 
 
The mean length of admission for all diabetic patients in the study was 13.04 ± 9.29 days 
vs. 8.86 ± 8.33 days for non-diabetic patients; p<0.00001 (see Figure 4.2). When 
comparing within groups, diabetic patients were admitted for a significantly longer period 
of time than the non-diabetic patients in the cardiovascular diseases (CVS) (p=0.006), 
ophthalmic (p<0.0001), renal (p=0.0002) and cerebrovascular diseases (CVD) (p=0.002) 
groups. However, there were no significant differences in the length of stay for the 
peripheral vascular diseases (PVD) (p=0.3) and the neurological diseases (p=0.4) groups 
respectively.  
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Fig 4.2 Average hospital stay per patient 
 
4.4 Total costs of hospitalisation 
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Average total hospitalisation costs per patient for diabetic patients were significantly 
higher than those for the non-diabetic patients with mean total costs of R27 216-06 
± R19 476-65 for all diabetic subjects compared to R18 185-05 ± R16 725-90 p<0.0001 
for the non-diabetic patients. Average total costs within disease groups were significantly 
higher in the diabetic group than in the non-diabetic group for CVS (p=0.004), ophthalmic 
(p<0.00001), renal (p=0.0002), and CVD (P=0.003). However, in the PVD and neurology 
groups, there was no significant difference in the total cost of hospitalisation with p= 0.3 
for PVD and p=0.4 for the neuropathy group respectively as shown in Figure 4.3. Diabetic 
patients in the neuropathy and cerebrovascular diseases group were the most expensive 
due to the longest stay encountered in this group of patients. 
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Fig 4.3 Average total cost of hospitalisation per patient 
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4.5 Cost of pharmaceuticals 
 
The total cost of pharmaceuticals for all diabetic cohorts was R282 804-14 while for non-
diabetic patients it was R282 587-01. The mean cost per patient for diabetic patients was 
significantly more than that for non-diabetic patients, R1 824-54 ± R1 590-82 vs. R1 121-
38 ± R1 297-90; respectively, p<0.00001. The cost of pharmaceuticals in the diabetic 
group was significantly higher for the CVS (p=0.004), ophthalmic (p<0.0001), renal 
(p=0.0003) and CVD (p=0.02) groups. However there was no significant difference found 
in the neurological (p=0.13) and PVD (p=0.2) groups, see Figure 4.4 below. 
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Fig. 4.4 Average cost of pharmaceuticals per patient 
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4.6 Cost of laboratory tests and procedures 
 
The total cost of all laboratory tests and medical procedures for all diabetic patients was 
R192 473-02 and R164 712-38 for all non-diabetic patients. The mean cost per patient of 
laboratory tests and procedures was significantly higher for diabetic patients than for the 
non-diabetic patients R1 241-76 ± R1 443-30 vs. R653-62 ± R543-72; p<0.0001, see 
Figure 4.5 below. Within disease groups diabetic patients’ mean costs were significantly 
higher than those of non-diabetic patients in the CVS (p=0.001), ophthalmic (p=0.0002), 
renal (p=0.001), PVD (p=0.0004) and CVD (p=0.004). However, there was no significant 
difference in the average laboratory costs between the diabetic and the non-diabetic 
patients in the neurology group with p=0.5.   
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Fig. 4.5 Average cost of laboratory tests and procedures per patient 
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4.7 Average rate of hospitalisation per patient per year (in 2009)  
Diabetic patients had a significantly higher average hospitalisation rate per patient of 1.8 ± 
0.8 times compared to 1.5 ± 0.6 times per year in 2009, p<0.00001, Figure 4.6. Within the 
disease groups, the average frequency of hospitalisation per patient for the year 2009 was 
significantly higher in diabetic patients than in non-diabetic patients for cardiovascular (p= 
0.013), renal (p=0.003) and cerebrovascular (p=0.0000934) conditions. However, no 
significant difference was seen in the ophthalmic (p=0.25), peripheral vascular (p=0.41) 
and neurological groups (p=0.29). 
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Chapter 5 Discussion and Limitations 
5.1 Discussion 
 
The prevalence of diabetes among the study sample was 38.08% (N=407). This group of 
diabetic patients was not accounted for on Medicom since secondary diagnoses are not 
documented. This is a common problem as noted in many studies that hospital databases 
under-report diabetes for in-patient related discharges by as much as 40%, a challenge 
especially in patients with co-morbidities (McCandless 2002).  
 
Cardiovascular disease was the most prevalent in the both groups, (31.3 % of the non-
diabetic patients studied and 38% of the diabetic patients). When combined cardiovascular 
patients in both groups were the most expensive and were in the majority, further 
highlighting the grave danger of the rise of cardiovascular diseases in the community. This 
is not a new trend as explained by the IDF (2003)
 
that cardiovascular complications 
frequently account for the bulk of the costs as reflected in the patterns of hospital 
admissions for the treatment of complications. Jiang et al (2002) in USA and Gargliardino 
et al (2000) in the Argentinean study also found the same trend.  
 
 
Diabetic patients were hospitalised for longer periods than non-diabetic patients; 13.04 ± 
9.29 days vs. 8.86 ± 8.33 days, (p<0.001). The length of stay for the non-diabetic patients 
in the present study is comparable to the average of 5.9 days for all patients discharged in 
December 2009 as calculated by the CHBAH’s Information Technology department. This 
shows that the non-diabetic patients studied were within the overall hospital range, further 
consolidating the accuracy of this study while the diabetic patients stayed for longer. These 
findings for length of hospitalisation of diabetic patients are close to the results obtained 
by Van Zyl and Rheeder (2009) for Kalafong hospital who reported a median stay of 7.5 
days with a range of 1 to 87 days. Diabetic patients in the current study were hospitalized 
for longer than the patients studied in Groote Schuur hospital by Pepper et al (2007). In 
that study the mean length of stay for diabetic patients was 4 days. This could be explained 
by the fact that in Groote Schuur, Pepper et al (2007) were only investigating 
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hyperglycemic emergencies which in certain cases can be managed in a relatively shorter 
period of time. However, the results are consistent with the findings of studies done by 
Soltani et al (1993) in Tunisia, Carral et al (2002) in Spain and Colin et al (2007) in 
France. Soltani et al (1993) found a mean length of hospital stay of 10.3 days for diabetic 
patients vs. 8 days for the non-diabetic study population. In the Spanish study by Carral et 
al (2002), the mean duration of hospital admission was 12.5 ± 14.5 days for diabetic 
patients and 8.5 ± 10.6 days for the non-diabetic patients. In the study done by Colin et al 
(2007) the mean length of stay per condition ranged from 6 to 16.3 days for diabetic 
subjects and from 4.7 to 13.5 days for non-diabetic patients.  
 
The length of stay for all the patients studied ranged from 1 day to 49 days. From this 
perspective patients only admitted for a day at CHBAH seemingly are the less serious 
cases which could be seen at lower levels of care if a proper referral system is in place. In 
this regard the community should be sensitised about the advantages of following the 
proper referral system so that only the cases deserving to be attended to in a tertiary 
hospital are seen at CHBAH with the relevant resources and this might improve the 
allocative efficiency of resources in the institution. In addition the admission policy needs 
to be interrogated to determine how hospitalisation decisions are made. 
 
According to the Uniform Patient Fee Schedule released in November 2009, the facility 
fees for the different levels of care i.e. chronic care, day patient, general ward, high care 
ward to Intensive Care Unit (ICU) ranged from R269 for a chronic care facility to R2 793 
for ICU with a median of R1105-00 (general ward). The facility fees are gazetted by the 
national government for all hospitals. It is the fee that a fee- paying patient would pay in 
any public hospital. However PDE costs are calculated by the individual hospitals based 
on their actual expenditure and their actual patient numbers as described in the 
methodology. Although not used for charging patients per se, PDE costs are a more 
accurate reflection of what it costs the hospital to care for a patient for a day. 
 
On the other hand, the average PDE cost used in this study was R1 851-66, about 50% 
more than the facility fee gazetted for a general ward fee. This PDE calculated for the 
study seems very high which could raise questions about allocative efficiency of resources 
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at CHBAH. It could mean that there is a disproportionate expenditure to the patient day 
equivalents or both patient volumes and expenditure are inappropriately high. There is 
room to improve the costing functions at CHBAH so as to allow for a wider and deeper 
research with more reliable and accurate results.  
 
The diabetic subjects had significantly higher overall total hospitalisation costs, 
pharmaceuticals and laboratory and procedures’ costs. This is expected due to diabetic 
patients’ longer duration of stay. Hospital in-patient costs for the treatment of diabetes 
complications are the largest single contributor to direct healthcare costs (IDF 2003). The 
present study’s findings concurred with this. From the study results, 118 of the 155 (76.1 
%) diabetic patients were on some form of insulin and this might have contributed to the 
higher cost of pharmaceuticals for diabetic patients. Laboratory and procedure costs for 
diabetic patients were significantly higher than costs for non-diabetic patients. This could 
be explained by the more stringent requirements for diabetic care monitoring. However, 
the higher costs in the diabetic study patients are not necessarily attributable to the 
presence of diabetes alone because this study is of a purely descriptive nature and the 
confounding factors like age, gender, race, weight, etc. were not controlled.  
 
There could have been an under-estimate of pharmaceutical and procedures because for 
pharmaceuticals and laboratory costs, the researcher had to rely on the handwritten data in 
the medical records. In most instances it was not stated what tests had been done or any 
procedures carried out and the only information that was accurately available was the 
length of hospitalisation which is a direct determinant of lodging costs. In addition, the 
prices of pharmaceuticals availed were much lower than the government gazetted single 
exit prices which was not clear whether the prices are what the government actually pays 
the pharmaceutical companies taking advantage of economies of scale or the data had 
simply not been updated. For instance the single exit prices extracted from Monthly Index 
of Medical Specialties (MIMS) of July 2009, a pack of 50 Cyclosporine 25 mg capsules 
had a price of R499-25 for the cheaper generic equivalent and the brand being used at 
CHBAH (Sandimmun Neoral)) cost R602-10 yet the price list at CHBAH quoted the same 
product at a cost of R175.48 as at March 2009. This could have also contributed to the low 
cost values associated with pharmaceuticals in this study. 
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This study also looked at the hospitalisation frequency for the patients for the year 2009. 
Diabetes patients had a significantly higher average frequency of hospitalisation per 
patient for the year 2009, for cardiovascular, renal and cerebrovascular conditions. This 
could be explained by the complications associated with renal failure such as the constant 
need for dialysis which require chronic in-patient care. Cardiovascular disease is also the 
major complication of type 2 diabetes and is responsible for more than 50% and up to 80% 
of deaths in people with diabetes as well as for very substantial morbidity and loss of 
quality of life (IDF 2003). There was no significant difference in the frequency of 
hospitalisation for ophthalmic, peripheral vascular disease and neuropathy patients. This 
could be explained by small sample sizes and the fact that some patients have more than 
one GT or GP number which was used in the study to ascertain the rate of hospitalisation. 
 
. 
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 5.2 Limitations of the study 
 Records of patients who died in hospital where not included in the study which might 
have caused an underestimate of diabetes costs as diabetes is a major cause of 
mortality. 
 The researcher did not have access to all medical records as some were presumed lost 
or were still in the wards, which is a major limitation of retrospective data analyses. 
 A small sample size and a short study period used in the comparison of diabetic and 
non-diabetic patients within specific disease groups means that the study results cannot 
be generalized to all patients seen at CHBAH or to South Africa as a whole. 
 Using the month of December may have distorted the morbidity patterns because there 
are fewer patients admitted to CHBAH due to the holidays in that month. However 
there was no major difference in discharge numbers in December relative to the other 
months (appendix 2) and hence the month of December was chosen to simplify data 
extraction for the annual hospitalisation frequency. 
 Although Medicom® is a fairly comprehensive data capturing system; it is not fully 
utilized at CHBAH. Important sections like medication prescribed and actually given 
to the patient, procedures and tests carried out are left blank. The researcher had to rely 
on the hand written records to decipher the relevant information with the assumption 
that what was found was all there was to the file yet in reality it may not  be so. This 
weakens a retrospective analysis when compared with a prospective one under these 
circumstances. 
 In some instances one hospital number had been issued to more than one patient and in 
others one patient had more than one hospital number. In addition where a patient had 
more than one hospital number it distorts the information on admission rates by the 
same patient. 
 There was also the problem of categorising diseases like neuropathy on Medicom® 
only being referred to as pain. 
 Not all diabetic patients seen in December were included in the study. Those registered 
as hypoglycemic or hyperglycemic were not included so as to allow comparison of 
diabetic patients with non-diabetic patients of similar conditions. This caused an under 
estimate of the prevalence of diabetes in the community. 
- 
 46 
 It was not clear on Medicom® for the above mentioned patients whether the hypo- or 
hyperglycemia was the primary diagnosis or these conditions had been precipitated by 
other conditions e.g. peripheral vascular disease which effectively reduced the sample 
size. 
 The study only calculated the hospitalisation rate without looking at the reasons for 
hospitalisation. This information does not reflect much on the trends of morbidity and 
especially in diabetic patients were re-hospitalisation may be a function of poor 
glycemic control. 
 Cost data for pharmaceuticals was not the same as the single exit price gazetted by the 
government which led to a low value for pharmaceuticals. 
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Chapter 6 Conclusions and recommendations 
6.1 Conclusions  
Within specific disease groups, this study showed that diabetic patients discharged in 
December 2009 from the CHBAH wards consume on average significantly more resources 
than non-diabetic patients with similar conditions. Diabetic patients had a longer duration 
of hospitalisation and their total hospitalisation costs were 44% more than that of non-
diabetic patients. The greatest numbers of patients in both groups had cardiovascular 
diseases. 
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6.2 Recommendations 
 
 Data capture clerks and medical personnel need to be sensitised to the importance of 
accurate data management. Their appreciation of the fact could be enhanced by 
availing to them the research findings from the data systems they use, so that they can 
have a better understanding and a willingness to co-operate (WHO 1999) 
 A comprehensive financial accounting system and a computerized database for 
resource consumption by individual patients is required so that costing studies can be 
done accurately. 
 The referral system should be effectively implemented to avoid unnecessary 
congestion at tertiary hospitals.  
 Further prospective studies on diabetes cost should be carried out on larger samples 
and for a longer duration. 
 Admissions policy needs to be reviewed, especially where ambulatory care is a 
possible alternative. 
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6.3 Implications for the pharmacist 
 
 As the health care professional most accessible to the general public, pharmacists should 
be actively involved in diabetes prevention efforts in communities by encouraging healthy 
lifestyles, being involved in diabetes care , patient education and blood sugar monitoring  
with active follow up on those found to be having diabetic symptoms or inadequate control 
of established diabetes.  
 Pharmacists should play an active role in clinical pharmacy as part of the Outpatient 
clinics in hospitals where pharmacists interact with patients at their level and educate them 
on medicines identification and compliance with their treatment so as to reduce 
hospitalisation episodes. 
 Improved stock management is a pre-requisite for optimal diabetic care. By ensuring 
consistent adequate supplies of quality medications to both non-diabetic and diabetic 
patients, many hospitalisation episodes can be avoided. 
 Patients need to be educated by trained pharmacists regarding the use of their 
medicines especially the use of insulin particularly when vials are switched with flexi-pens 
due to supplier problem or unavailability of one or the other. 
 Pill counting may be a possible alternative in monitoring patients’ compliance with 
medication. This could also be handy in situations where there is a change of packaging 
due to a change in supplier which often happens due to the tendering process in place in 
public institutions. 
 Pharmacists can also be involved at ward level to enhance pharmaceutical care by, 
ensuring appropriate and rational drug selection which might improve patient care and 
potentially reduce costs. 
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Appendices 
1. DATA COLLECTION FORM 
DII ABETII C       Yes                    No                               MALE                FEMALE     
GT number  
Age  
Number of previous admission episodes in the 12months  
prior to current admission episode 
 
Diagnosis on current discharge  
Length of current hospitalisation  
 
Drugs 
Drug Quantity Cost/Unit Total Cost 
    
    
    
    
    
    
    
    
Total  
 
Laboratory Tests 
Test Quantity Cost/unit Total cost 
    
    
    
    
    
Total  
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Procedures 
Procedure Quantity Cost/unit Total cost 
    
    
    
Total  
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2. CHRIS HANI BARAGWANATH ACADEMIC HOSPITAL INPATIENT 
ADMISIONS AND DISCHARGES BY MONTH 2009  
(Extracted from Indicators Management Report, 2009) 
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3. MEDICAL SUPPLIES PRESCRIBED FOR THE STUDY PATIENTS 
 
ITEM PRICE 
ABCIXIMAB (C 7E3 FAB) INJECTION 2MG/ML; 5ML 3 559.61 
ACETAZOLAMIDE TABLETS 250MG;30'S 56.02 
ADENOSIDE INJECTION 3MG/ML; 2ML 127.29 
ADULT TOTAL PARENTERAL NUTRITION ITN 5004  BAG 1380.17 
ADULT TOTAL PARENTERAL NUTRITION ITN 8005A BAG 1491.36 
ALFACALCIDOL CAPSULES 0,25MCG; 30'S 116.43 
ALFACALCIDOL CAPSULES 1,0MCG; 30'S 378.51 
ALLOPURINOL TABLETS 100MG; 500'S 26.15 
ALLOPURINOL TABLETS 300MG; 30'S 98.52 
AMIODARONE HCL INJECTION 50 MG/ML; 3ML 46.18 
AMIODARONE HYDROCHLORIDE TABLETS 200MG; 30'S 32.51 
AMITRIPTYLINE HCL TABLETS PATIENT READY PACK: 25MG;28'S 42.96 
AMLODIPINE BESYLATE TABLETS 5MG; 30'S 5.25 
AMOXYCLAV 625MG TABLETS; 15 17.14 
AMOXYCLAV 1.2G INJECTION 21.38 
AMPHOTERICIN B INJECTION ; 50MG/VIAL 230.85 
AMPICILLIN SODIUM INJECTION: 250MG  PER VIAL 5.36 
ATENOLOL INJECTION 0,5MG/ML; 10ML 40.00 
ATENOLOL TABLETS 50MG; 28'S 14.97 
ATORVASTATIN TABLETS 10MG ;30'S 26.79 
ATORVASTATIN TABLETS 20MG;30'S 33.06 
ATROPINE SULPHATE OPHTHALMIC DROPS 1%;0,5ML;20'S 169.00 
BETAMATHASONE SODIUM PHOSPHATE 0.1%; EYE OINTMENT: 3G 47.03 
BETAMETHASONE;5ML INJECTION 105.00 
BETAXOLOL 5MG/ML OPHTHALMIC DROPS; 5ML 27.15 
BEZAFIBRATE CONTROLLED RELEASE TABLETS 400MG; 30'S 95.36 
BIMATOPROST,OPTHALMIC DROPS 0,3MG/ML;3ML 32.00 
BIPERIDEN HYDROCHLORIDE TABLETS 2MG; 500'S 70.98 
BUSERELIN ACETATE IMPLANT 9,9MG;3-MONTH DEPOT IMPLANT; 1 368.00 
CALCIFEROL TABLETS 50000IU; 100'S 161.64 
CALCIUM CARBONATE AND GLYCINE TABLETS 420MG /180MG; 28S 8.72 
CALCIUM CHLORIDE INJECTION 10%; 10ML 2.41 
CAPTOPRIL TABLETS 25MG; 56'S 12.00 
CARBAMAZEPINE CONTROLLED RELEASE TABLETS 200MG; 30'S 14.36 
CARBIDOPA AND LEVODOPA TABLETS 25MG;100MG; 100'S 73.26 
CARBIMAZOLE TABLETS: 5MG; 100'S 302.07 
CARVEDILOL TABLETS 12,5MG;30'S 23.54 
CARVEDILOL TABLETS 25MG; 30'S 25.95 
CARVEDILOL TABLETS 6,25MG;30'S 22.36 
CEFEPIME INJECTION; 2G/VIAL 22.42 
CEFTAZIDIME FOR INJECTION: 2G PER VIAL 49.37 
CEFTRIAXONE SODIUM FOR INJECTION 1GM PER VIAL;W/OUT DILUENT 24.86 
CEFUROXIME SODIUM FOR INJECTION: 750MG PER VIAL 9.80 
CHLORAMPHENICOL AND DEXAMETHASONE EYE DROPS: 0,5%;0,1%; 5ML 21.63 
CHLORAMPHENICOL EYE DROPS 0.5%; 10ML 22.71 
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CHLORAMPHENICOL EYE OINTMENT 1%; 3,5GM 11.67 
CHLORAMPHENICOL SODIUM SUCCINATE IV INJECTION: 1G/VIAL 8.16 
CICLOSPORIN CAPSULE: 100MG; 50'S 601.92 
CICLOSPORIN CAPSULES: 25MG; 50'S 175.48 
CIPROFLOXACIN HCL 3.5MG/ML EYE DROPS; 5ML 27.55 
CITALOPRAM (AS HYDROBROMIDE) TABLETS 20MG; 28'S 41.51 
CLARITHROMYCIN INJECTION: 500MG/VIAL 120.50 
CLARITHROMYCIN TABLETS XL(MODIFIED RELEASE);500MG;10'S 89.63 
CLINDAMYCIN PHOSPHATE INJECTION: 600MG PER 4ML AMPOULE 32.00 
CLONIDINE HYDROCHLORIDE TABLETS 25MCG; 100'S 36.64 
CLOPIDOGREL HYDROGEN SULPHATE TABLETS 75MG;30'S 24.97 
CLOTRIMAZOLE VAGINAL CREAM: 10MG/G W/SIX APPLICATORS; 50G 5.98 
CLOXACILLIN SODIUM FOR INJECTION 250MG 4.99 
CYCLOPENTOLATE HCL OPHTHALMIC DROPS;1%;0,5ML;20'S 169.00 
DABIGATRAN 110MG 30S (PRADAXA) 223.65 
DABIGATRAN 75MG 30S 222.60 
DEXAMETHASONE 0,1% EYE DROPS; 5ML 11.84 
DEXAMETHASONE INJECTION 4MG/ML; 1ML 3.39 
DEXMEDETOMIDINE HCL INJECTION PRECEDEX;100MG/ML 1 584.60 
DEXTROSE INJECTION IV SOLUTION;20%;PLASTIC;500ML;1'S 29.77 
DIAZOXIDE CAPSULES 25MG;100'S 415.45 
DICLOFENAC SODIUM TABLETS;25MG;42'S 3.00 
DICLOPHENAC INJECTION 75MG/3ML 37.79 
DIGOXIN TABLETS;0,25MG; 14'S 5.74 
DILTIAZEM HCL TABLETS: SLOW RELEASE 90MG; 60'S 43.79 
DILTIAZEM TABLETS 60MG; 50'S 35.21 
DIPYRIDAMOLE TABLETS 25MG;100'S 51.54 
DOXAZOSIN MESYLATE TABLETS: 4MG; 30'S 99.11 
ENALAPRIL MALEATE TABLETS 10MG; 28'S 39.27 
ENALAPRIL MALEATE TABLETS:20MG;28'S 29.36 
ENOXAPARIN INJECTION 80MG/0,8ML; 16.43 
ENOXAPARIN INJECTION: 40MG/0,4ML; 1'S 12.76 
EPLERENONE (INSPRA) 50MG 351.13 
EPTIFIBATIDE INJECTION 0,75MG/ML;100ML 1 463.57 
ERYTHROMYCIN STEARATE 250MG CAPSULES; 20'S 7.93 
ERYTHROPOIETIN FOR INJ  IV/SUBCUT;HUMAN RECOMBINANT;30 000IU; 0,6ML 900.00 
ERYTHROPOIETIN RECOMBINANT HUMAN; 4000 IU/AMP 143.37 
ERYTHROPOIETIN,RECOMBINANT HUMAN; 10000 IU/1ML  300.00 
ESTROGENS CONJUGATED TABLETS :0,625MG;500'S 71.29 
ESTROGENS CONJUGATED TABLETS :1,25MG;500'S 1 000.50 
FLUCONAZOLE CAPSULES 200MG; 28'S 164.12 
FLUCONAZOLE INJECTION  2MG/ML; 100ML 148.20 
FLUORESCEIN SODIUM OPHTHALMIC SOLUTION 2%;0,5ML;20'S 147.99 
FLUOROMETHOLONE 0.1% EYE DROPS; 5ML 14.10 
FLUOXETINE HCL TABLETS 20MG; 30'S 43.85 
FUROSEMIDE INJECTION 10MG/ML; 5ML 1.08 
FUROSEMIDE TABLETS 40MG;28'S 1.50 
FUSIDATE SODIUM IV; 500MG/VIAL 153.85 
FUSIDATE SODIUM TABLETS 250MG; 100'S 1 858.50 
FUSIDIC ACID ANHYDROUS 10MG /G;EYE DROPS; 5G 36.89 
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GABAPENTIN CAPSULES 100MG; 100'S 48.79 
GABAPENTIN CAPSULES 300MG; 100'S 73.93 
GANCICLOVIR SODIUM INJECTION 500MG/VIAL; 1'S 383.74 
GLIBENCLAMIDE TABLETS 5MG; 28'S 11.20 
GLICLAZIDE TABLETS 80MG; 60s 31.50 
GLUCAGON INJECTION; 1MG/VIAL PLUS DILUENT AND SYRINGE; KIT 84.29 
GLUCOSE INJECTION 35% 1000ML ; 1'S 29.78 
GLYCERYL TRINITRATE INJECTION 1MG/ML; 50ML 70.06 
GLYCERYL TRINITRATE TABLETS 0,5MG; 50'S 26.21 
GOSERELIN INJECTION 10,8MG;DEPOT;SINGLE DOSE APPLICATOR 1 767.00 
HEPARIN SODIUM INJECTION 5000IU/ML; 5ML 21.11 
HOMATROPINE HBR / HYPROMELLOSE EYE DROPS; 2% /0,5%; 5ML 8.96 
HYDRALAZINE TABLETS 10MG; 500'S 87.58 
HYDRALAZINE TABLETS 25MG; 500'S 166.66 
HYDROCHLOROTHIAZIDE TABLETS 25MG; 28'S 2.19 
HYOSCINE BUTYLBROMIDE TABLETS 10MG;100'S 33.28 
ILOPROST INJECTION 0,05MG/0,5ML;0,5ML 710.22 
IMIPENEM/ CILASTATIN SODIUM FOR INJECTION :500MG / 500MG;VIAL; 1'S 121.10 
INDAPAMIDE TABLETS 2,5MG; 30'S 5.36 
INSULIN INJ: HUMAN, BIOSYNTHETIC, E-COLI , SOLUBLE 30%, ISOPHANE 70%; 
100IU/ML; 10ML 69.65 
INSULIN INJECTION: HUMAN; BIOSYNTHETIC/E-COLI DERIVATIVE; SOLUBLE; 
100U/ML; 10ML 69.65 
INSULIN INJECTION: ISOPHANE, HUMAN, BIOSYNTHETIC; E-COLI DERIVATIVE; 
100U/ML; 10ML 69.65 
ISOSORBIDE DINITRATE INJECTION 1MG/ML; 10ML 56.21 
ISOSORBIDE DINITRATE TABLETS :10MG;50'S 7.12 
ISOSORBIDE DINITRATE TABLETS :SUBLINGUAL;5MG;50'S 5.20 
ISOSORBIDE MONONITRATE TABLETS 20MG;56'S 24.92 
IVABRADINE Donated 
LABETALOL HCL INJECTION 5MG/ML; 20ML 13.95 
LATANOPROST EYE DROPS 5MG/ML;2.5ML 49.00 
LENS,OPHTHALMIC,SPHERE INTRA OCULAR LENS FOR PLACEMENT IN ANTERIOR 
CHAMBER; 5 485.33 
LENS,OPHTHALMIC,SPHERE INTRA OCULAR LENS FOR PLACEMENT IN POSTERIOR 
CHAMBER; 518.56 
LENS,SURGICAL INTRA-OCULAR;ANTERIOR;POLYPROPYLENE;DIOPTER 
23;MANIPULATION HOLES; 245.00 
LENS,SURGICAL INTRA-OCULAR;ANTERIOR;POLYPROPYLENE;DIOPTER 
24;MANIPULATION HOLES; 1 995.00 
LEVOBUNOLOL 0.5% EYE DROPS; 5ML 15.95 
LEVOCABASTINE 0.5MG/ML EYE DROPS; 4ML 75.39 
LEVOTHYROXINE SODIUM TABLETS;100UG;28'S 21.14 
LEVOTHYROXINE SODIUM TABLETS;50UG;28'S 14.77 
LIGNOCAINE HCL INJ 1% ; 20ML 10.41 
LINEZOLID INJECTION 600MG/300ML;300ML 260.50 
LINEZOLID TABLETS 600MG;10'S 2 565.86 
LIOTHYRONINE SODIUM TABLETS 20MCG; 50'S 66.91 
LODOXAMIDE (AS TROMETHAMINE) EYE DROPS: 1MG/ML; 10ML 40.46 
LOSARTAN TABLETS 50MG;30'S 17.10 
LUBRICANT,OPHTHALMIC ANHYDROUS LIQUID LANOLIN 3% AND MINERAL OIL TO 
100%; 3,5G 55.19 
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MAGNESIUM CHLORIDE SLOW RELEASE TABLETS 535MG;60'S 23.94 
MEROPENEM TRIHYDRATE ANHYDROUS INJECTION; 500MG/VIAL 223.82 
METFORMIN HYDROCHLORIDE TABLETS;850MG;56'S 68.57 
METHYLDOPA TABLETS 250MG; 84'S 224.90 
METOPROLOL 100MG TABS 40S  136.94 
METRONIDAZOLE INJECTION I.V. INFUSION;500MG/100ML;;20'S 678.84 
METRONIDAZOLE TABLETS;400MG;21'S 22.75 
MINOXIDIL TABLETS 10MG; 100'S 428.27 
MINOXIDIL TABLETS 5MG; 100'S 244.76 
MITOMYCIN INJECTION; 10MG/VIAL; 1'S 485.40 
MUPIROCIN 2% TOPICAL OINTMENT; 15G 26.23 
MYCOPHENOLATE MOFETIL CAPSULES 250MG;100'S 410.32 
MYCOPHENOLATE MOFETIL TABLETS 500MG;50'S 775.61 
MYCOPHENOLATE SODIUM TABS 384.8MG (EQUIVALENT TO 360MG MYCOPHENOLIC 
ACID);120'S 1 243.45 
MYCOPHENOLATE SODIUM TABS FILM-COATED;192.4MG ( EQ TO 180MG 
MYCOPHENOLIC ACID);120'S 621.96 
NATAMYCIN OPHTHALMIC SUSPENSION 50MG/ML;;15ML 1 288.31 
NIFEDIPINE TABLETS 30MG;CONTROLLED RELEASE;28'S 16.92 
NIMODIPINE 30MG TABLETS; 100S 663.27 
NITROGLYCERIN AEROSOL 0,4MG/METERED DOSE; 200 DOSE UNIT 119.70 
OESTRADIOL TABLETS 2MG; 28'S 95.77 
OMEPRAZOLE CAPSULES 20MG; 28'S 15.44 
OXYBUPROCAINE HCL OPHTHALMIC SOLUTION 0,4%(BENOXINATE HCL);0,5ML 
MINIMS;20'S 169.00 
OXYBUTYNIN HYDROCHLORIDE TABLETS 5MG; 100'S 25.31 
OXYMETAZOLINE HYDROCHLORIDE 0.025% EYE DROPS: 15ML 11.95 
PANTOPRAZOLE POWDER FOR INJECTION 40MG;10ML 57.92 
PARACETAMOL SOLUTION FOR INFUSION 1G/100ML;100ML VIAL 36.48 
PARACETAMOL,CODEINE PHOSPH,MEPBROBAMATE,AND CAFFEIN 320MG;8MG;150MG 
AND 32MG TABLETS; 500'S 68.34 
PENTOXIFYLLINE TABLETS :SLOW RELEASE 400MG; 100'S 172.00 
PERINDOPRIL TERBUTYLAMINE TABLETS 4MG;28'S 14.36 
PILOCARPINE HYDROCHLORIDE 2% EYE DROPS: 15ML 31.75 
PILOCARPINE HYDROCHLORIDE OPHTHALMIC GEL 4%; 5G 54.71 
PIPERACILLIN 4G AND TAZOBACTAM 500MG INJECTION;POWDER FOR 
RECONSTITUTION IN 50ML VIAL 102.19 
PLASMINOGEN ACTIVATOR (RECOMBINANT HUMAN TISSUE TYPE); INJECTION 
50MG/VIAL; 1'S 3 510.14 
PRAZOSIN TABLETS 1MG;30 91.78 
PRAZOSIN TABLETS 2MG; 30 157.64 
PREDNISOLONE ACETATE 1% EYE DROPS; 5ML 39.63 
PREDNISONE TABLETS 5MG;28'S 2.18 
PROCHLORPERAZINE MESYLATE INJECTION 12,5MG/ML; 1ML 4.45 
PROCHLORPERAZINE MESYLATE TABLETS 5MG; 250'S 18.80 
PROPOXYPHENE HYDROCHLORIDE AND PARACETAMOL CAPSULES; 65MG AND 
250MG; 100'S 33.09 
PROPRANOLOL HYDROCHLORIDE TABLETS 40MG; 84'S 5.13 
RANITIDINE HYDROCHLORIDE INJECTION 25MG/ML; 2ML 49.90 
SHIELD, EYE;CARTELLA TYPE;LEFT OPULET; 1'S 14.90 
SHIELD;EYE;CARTELLA TYPE;RIGHT OPULET; 1'S 3.98 
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SIMVASTATIN TABLETS 10MG; 28'S 11.76 
SIMVASTATIN TABLETS 20MG; 28'S 14.80 
SODIUM CROMOGLYCATE 2% EYE DROPS: 10ML 134.53 
SODIUM HYALURONATE 16MG/ML; OPHTHALMIC SOLUTION; 0.8ML  487.00 
SODIUM VALPROATE INJECTION  400MG  123.63 
SOTALOL HYDROCHLORIDE TABLETS 160MG; 100'S 46.34 
SOTALOL HYDROCHLORIDE TABLETS 80MG; 100'S 30.75 
SPIRONOLACTONE TABLETS;25MG;28'S 7.65 
STREPTOKINASE FOR INJECTION 1 500 000IU/VIAL; 1'S 2 156.32 
SULPHASALAZINE EC 500MG TABLETS 100S 235.11 
TACROLIMUS CAPSULES 5MG;50'S 4 814.05 
TELMISARTAN TABLETS 40MG;28'S 212.56 
TELMISARTAN TABLETS 80MG;28'S 280.55 
TESTOSTERONE PROPIONATE, TESTOST PHENYLPROPIONATE, TESTOS. 
ISOCAPROATE, TESTOST DECANOATE:30MG;60MG;60MG;100MG/ML; 1ML 135.66 
THIAMINE HYDROCHLORIDE INJECTION VITAMIN B1 100MG/ML; 10ML 2.15 
THYROXINE TABLETS 0,05MG; 100'S 7.63 
THYROXINE TABLETS 0,1MG; 100'S 22.04 
TIMOLOL MALEATE 0.5% EYE DROPS; 5ML 53.83 
TOBRAMYCIN OPHTHALMIC SOLUTION USP: 3MG/ML; 5ML 102.61 
TOTAL PHOSPHOLIPIDS; FOR INTRATRACHEAL USE; 200MG/8ML VIAL 2 435.11 
TRAMADOL HYDROCHLORIDE CAPSULES 50MG; 100'S 67.68 
TROPICAMIDE EYE DROPS 1%;0,5ML;20'S 169.00 
VANCOMYCIN POWDER FOR INJECTION USP; 1000MG/VIAL 82.08 
VENLAFAXINE TABLETS 75MG; 30'S 113.73 
VERAPAMIL HYDROCHLORIDE INJECTION 2,5MG/ML; 2ML 0.89 
VERAPAMIL HCL  SUSTAINED RELEASE TABLETS 240MG; 30'S 480.64 
VITAMIN  TABLETS;25MG VIAL;28'S 1.16 
VORICONAZOLE POWDER FOR INJECTION 200MG/;FOR INFUSION 340.50 
WARFARIN 5MG TABLETS; 100S 221.02 
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4 ETHICS CLEARANCE 
 
- 
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5. PROTOCOL APPROVAL 
 
